Abstract 7459: The anticancer effects of brusatol are mediated by PPAR-γ/ME1-driven glycolysis in intrahepatic cholangiocarcinoma Article Swipe
Xiaoqing Wang
,
Caiming Xu
,
Kai Luo
,
Y Fang
,
Ajay Goel
,
Guixin Zhang
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1158/1538-7445.am2025-7459
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1158/1538-7445.am2025-7459
Background: Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor characterized by its dense fibrotic microenvironment, which is associated with chemotherapy resistance and poor outcome. Hence, developing novel strategies to improve the outcome of ICC is essential. Brusatol, a steroidal molecule isolated from Brucea javanica, exhibits various biological activities, including anti-inflammatory and anticancer effects. Although the molecular mechanisms underlying the anti-cancer effects of brusatol in ICC remain unclear, the present study aims to investigate its therapeutic potential in ICC cells. Methods: We conducted a series of in vitro experiments on human ICC cell lines (HCCC-9810 and HuCCT1) to assess the impact of brusatol on cell proliferation and glycolysis regulation. Transcriptomic sequencing and pathway enrichment analysis was performed to identify specific signaling pathways associated with brusatol treatment in ICC cells. Furthermore, the pathway was further validated through a series of mechanistic studies. Results: Brusatol significantly inhibited the proliferation, migration, and invasion of ICC cells in a concentration-dependent manner (p < 0.05). Glycolytic activity was markedly suppressed by brusatol, as evidenced by a reduction in glucose consumption, ATP production, and lactate secretion in ICC cells. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay confirmed the downregulation of glycolysis-related genes, including GLUT1, HK2, PFK1, and LDHA. RNA sequencing and pathway enrichment analysis suggested that brusatol inhibits the PPAR-γ/ME1 signaling pathway (p < 0.05), which likely regulates glycolysis in ICC cells. Subsequently, RT-qPCR and western blotting results corroborated the RNA-seq findings. Interfering with PPAR-γ expression via siRNA or inhibiting the PPAR-γ pathway with Rosiglitazone resulted in a marked reduction in glycolytic activity (p < 0.01), further reinforcing the critical role of the PPAR-γ/ME1 signaling axis in the regulation of glycolysis. These findings underscore the potential of brusatol as a therapeutic agent that effectively disrupts glycolytic metabolism in ICC by targeting the PPAR-γ/ME1 pathway. Conclusion: Our findings provide compelling evidence that the PPAR-γ/ME1 signaling pathway mediates the anti-cancer effects of brusatol, supporting its potential as a safe and effective integrative treatment approach for ICC. This potential offers hope for the development of new and improved treatments for ICC. Citation Format: Xiaoqing Wang, Caiming Xu, Kai Luo, Yuhan Fang, Goel Ajay, Guixin Zhang. The anticancer effects of brusatol are mediated by PPAR-γ/ME1-driven glycolysis in intrahepatic cholangiocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7459.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1158/1538-7445.am2025-7459
- OA Status
- hybrid
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4409631245
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4409631245Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1538-7445.am2025-7459Digital Object Identifier
- Title
-
Abstract 7459: The anticancer effects of brusatol are mediated by PPAR-γ/ME1-driven glycolysis in intrahepatic cholangiocarcinomaWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-04-21Full publication date if available
- Authors
-
Xiaoqing Wang, Caiming Xu, Kai Luo, Y Fang, Ajay Goel, Guixin ZhangList of authors in order
- Landing page
-
https://doi.org/10.1158/1538-7445.am2025-7459Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1158/1538-7445.am2025-7459Direct OA link when available
- Concepts
-
Intrahepatic Cholangiocarcinoma, Glycolysis, Cancer research, Medicine, Peroxisome proliferator-activated receptor, Pharmacology, Internal medicine, Chemistry, Receptor, MetabolismTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4409631245 |
|---|---|
| doi | https://doi.org/10.1158/1538-7445.am2025-7459 |
| ids.doi | https://doi.org/10.1158/1538-7445.am2025-7459 |
| ids.openalex | https://openalex.org/W4409631245 |
| fwci | 0.0 |
| type | article |
| title | Abstract 7459: The anticancer effects of brusatol are mediated by PPAR-γ/ME1-driven glycolysis in intrahepatic cholangiocarcinoma |
| biblio.issue | 8_Supplement_1 |
| biblio.volume | 85 |
| biblio.last_page | 7459 |
| biblio.first_page | 7459 |
| topics[0].id | https://openalex.org/T11072 |
| topics[0].field.id | https://openalex.org/fields/13 |
| topics[0].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[0].score | 0.9957000017166138 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1312 |
| topics[0].subfield.display_name | Molecular Biology |
| topics[0].display_name | Peroxisome Proliferator-Activated Receptors |
| topics[1].id | https://openalex.org/T10631 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.989799976348877 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1306 |
| topics[1].subfield.display_name | Cancer Research |
| topics[1].display_name | Cancer, Hypoxia, and Metabolism |
| topics[2].id | https://openalex.org/T12996 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9884999990463257 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1305 |
| topics[2].subfield.display_name | Biotechnology |
| topics[2].display_name | Cancer Research and Treatments |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2909135397 |
| concepts[0].level | 2 |
| concepts[0].score | 0.6800234317779541 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q124292 |
| concepts[0].display_name | Intrahepatic Cholangiocarcinoma |
| concepts[1].id | https://openalex.org/C20251656 |
| concepts[1].level | 3 |
| concepts[1].score | 0.5790470838546753 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q162643 |
| concepts[1].display_name | Glycolysis |
| concepts[2].id | https://openalex.org/C502942594 |
| concepts[2].level | 1 |
| concepts[2].score | 0.5077227354049683 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[2].display_name | Cancer research |
| concepts[3].id | https://openalex.org/C71924100 |
| concepts[3].level | 0 |
| concepts[3].score | 0.4588954448699951 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[3].display_name | Medicine |
| concepts[4].id | https://openalex.org/C187345961 |
| concepts[4].level | 3 |
| concepts[4].score | 0.45852982997894287 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q419629 |
| concepts[4].display_name | Peroxisome proliferator-activated receptor |
| concepts[5].id | https://openalex.org/C98274493 |
| concepts[5].level | 1 |
| concepts[5].score | 0.3952066898345947 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[5].display_name | Pharmacology |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.3802724778652191 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C185592680 |
| concepts[7].level | 0 |
| concepts[7].score | 0.3234685957431793 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[7].display_name | Chemistry |
| concepts[8].id | https://openalex.org/C170493617 |
| concepts[8].level | 2 |
| concepts[8].score | 0.07368674874305725 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q208467 |
| concepts[8].display_name | Receptor |
| concepts[9].id | https://openalex.org/C62231903 |
| concepts[9].level | 2 |
| concepts[9].score | 0.07133045792579651 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1057 |
| concepts[9].display_name | Metabolism |
| keywords[0].id | https://openalex.org/keywords/intrahepatic-cholangiocarcinoma |
| keywords[0].score | 0.6800234317779541 |
| keywords[0].display_name | Intrahepatic Cholangiocarcinoma |
| keywords[1].id | https://openalex.org/keywords/glycolysis |
| keywords[1].score | 0.5790470838546753 |
| keywords[1].display_name | Glycolysis |
| keywords[2].id | https://openalex.org/keywords/cancer-research |
| keywords[2].score | 0.5077227354049683 |
| keywords[2].display_name | Cancer research |
| keywords[3].id | https://openalex.org/keywords/medicine |
| keywords[3].score | 0.4588954448699951 |
| keywords[3].display_name | Medicine |
| keywords[4].id | https://openalex.org/keywords/peroxisome-proliferator-activated-receptor |
| keywords[4].score | 0.45852982997894287 |
| keywords[4].display_name | Peroxisome proliferator-activated receptor |
| keywords[5].id | https://openalex.org/keywords/pharmacology |
| keywords[5].score | 0.3952066898345947 |
| keywords[5].display_name | Pharmacology |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.3802724778652191 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/chemistry |
| keywords[7].score | 0.3234685957431793 |
| keywords[7].display_name | Chemistry |
| keywords[8].id | https://openalex.org/keywords/receptor |
| keywords[8].score | 0.07368674874305725 |
| keywords[8].display_name | Receptor |
| keywords[9].id | https://openalex.org/keywords/metabolism |
| keywords[9].score | 0.07133045792579651 |
| keywords[9].display_name | Metabolism |
| language | en |
| locations[0].id | doi:10.1158/1538-7445.am2025-7459 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S168522863 |
| locations[0].source.issn | 0008-5472, 1538-7445 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0008-5472 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Cancer Research |
| locations[0].source.host_organization | https://openalex.org/P4310320273 |
| locations[0].source.host_organization_name | American Association for Cancer Research |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320273 |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Cancer Research |
| locations[0].landing_page_url | https://doi.org/10.1158/1538-7445.am2025-7459 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5100452945 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-9317-9983 |
| authorships[0].author.display_name | Xiaoqing Wang |
| authorships[0].countries | CN |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I191996457 |
| authorships[0].affiliations[0].raw_affiliation_string | 1Institute (College) of Integrative Medicine, Dalian Medical University, DaLian, China; |
| authorships[0].institutions[0].id | https://openalex.org/I191996457 |
| authorships[0].institutions[0].ror | https://ror.org/04c8eg608 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I191996457 |
| authorships[0].institutions[0].country_code | CN |
| authorships[0].institutions[0].display_name | Dalian Medical University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Xiaoqing Wang |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | 1Institute (College) of Integrative Medicine, Dalian Medical University, DaLian, China; |
| authorships[1].author.id | https://openalex.org/A5069379096 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-7794-2301 |
| authorships[1].author.display_name | Caiming Xu |
| authorships[1].countries | CN |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I191996457, https://openalex.org/I4210140813 |
| authorships[1].affiliations[0].raw_affiliation_string | 2Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, DaLian, China; |
| authorships[1].institutions[0].id | https://openalex.org/I191996457 |
| authorships[1].institutions[0].ror | https://ror.org/04c8eg608 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I191996457 |
| authorships[1].institutions[0].country_code | CN |
| authorships[1].institutions[0].display_name | Dalian Medical University |
| authorships[1].institutions[1].id | https://openalex.org/I4210140813 |
| authorships[1].institutions[1].ror | https://ror.org/055w74b96 |
| authorships[1].institutions[1].type | healthcare |
| authorships[1].institutions[1].lineage | https://openalex.org/I4210140813 |
| authorships[1].institutions[1].country_code | CN |
| authorships[1].institutions[1].display_name | First Affiliated Hospital of Dalian Medical University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Caiming Xu |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | 2Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, DaLian, China; |
| authorships[2].author.id | https://openalex.org/A5084711013 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-2303-5260 |
| authorships[2].author.display_name | Kai Luo |
| authorships[2].countries | CN |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I191996457, https://openalex.org/I4210100868 |
| authorships[2].affiliations[0].raw_affiliation_string | 3Department of General Surgery, The Second Affiliated Hospital of Dalian Medical University, DaLian, China; |
| authorships[2].institutions[0].id | https://openalex.org/I191996457 |
| authorships[2].institutions[0].ror | https://ror.org/04c8eg608 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I191996457 |
| authorships[2].institutions[0].country_code | CN |
| authorships[2].institutions[0].display_name | Dalian Medical University |
| authorships[2].institutions[1].id | https://openalex.org/I4210100868 |
| authorships[2].institutions[1].ror | https://ror.org/012f2cn18 |
| authorships[2].institutions[1].type | healthcare |
| authorships[2].institutions[1].lineage | https://openalex.org/I4210100868 |
| authorships[2].institutions[1].country_code | CN |
| authorships[2].institutions[1].display_name | Second Affiliated Hospital of Dalian Medical University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Kai Luo |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | 3Department of General Surgery, The Second Affiliated Hospital of Dalian Medical University, DaLian, China; |
| authorships[3].author.id | https://openalex.org/A5110403987 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Y Fang |
| authorships[3].countries | CN |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I191996457 |
| authorships[3].affiliations[0].raw_affiliation_string | 1Institute (College) of Integrative Medicine, Dalian Medical University, DaLian, China; |
| authorships[3].institutions[0].id | https://openalex.org/I191996457 |
| authorships[3].institutions[0].ror | https://ror.org/04c8eg608 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I191996457 |
| authorships[3].institutions[0].country_code | CN |
| authorships[3].institutions[0].display_name | Dalian Medical University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Yuhan Fang |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | 1Institute (College) of Integrative Medicine, Dalian Medical University, DaLian, China; |
| authorships[4].author.id | https://openalex.org/A5101530683 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-1396-6341 |
| authorships[4].author.display_name | Ajay Goel |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210110459, https://openalex.org/I4387156432 |
| authorships[4].affiliations[0].raw_affiliation_string | 4Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center, Monrovia, Monrovia, CA. |
| authorships[4].institutions[0].id | https://openalex.org/I4387156432 |
| authorships[4].institutions[0].ror | https://ror.org/05fazth07 |
| authorships[4].institutions[0].type | facility |
| authorships[4].institutions[0].lineage | https://openalex.org/I1301076528, https://openalex.org/I4387156432 |
| authorships[4].institutions[0].country_code | |
| authorships[4].institutions[0].display_name | Beckman Research Institute |
| authorships[4].institutions[1].id | https://openalex.org/I4210110459 |
| authorships[4].institutions[1].ror | https://ror.org/01z1vct10 |
| authorships[4].institutions[1].type | healthcare |
| authorships[4].institutions[1].lineage | https://openalex.org/I1301076528, https://openalex.org/I4210110459 |
| authorships[4].institutions[1].country_code | US |
| authorships[4].institutions[1].display_name | City of Hope |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Goel Ajay |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | 4Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center, Monrovia, Monrovia, CA. |
| authorships[5].author.id | https://openalex.org/A5100627957 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-3990-6024 |
| authorships[5].author.display_name | Guixin Zhang |
| authorships[5].countries | CN |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I191996457, https://openalex.org/I4210100868 |
| authorships[5].affiliations[0].raw_affiliation_string | 3Department of General Surgery, The Second Affiliated Hospital of Dalian Medical University, DaLian, China; |
| authorships[5].institutions[0].id | https://openalex.org/I191996457 |
| authorships[5].institutions[0].ror | https://ror.org/04c8eg608 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I191996457 |
| authorships[5].institutions[0].country_code | CN |
| authorships[5].institutions[0].display_name | Dalian Medical University |
| authorships[5].institutions[1].id | https://openalex.org/I4210100868 |
| authorships[5].institutions[1].ror | https://ror.org/012f2cn18 |
| authorships[5].institutions[1].type | healthcare |
| authorships[5].institutions[1].lineage | https://openalex.org/I4210100868 |
| authorships[5].institutions[1].country_code | CN |
| authorships[5].institutions[1].display_name | Second Affiliated Hospital of Dalian Medical University |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Guixin Zhang |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | 3Department of General Surgery, The Second Affiliated Hospital of Dalian Medical University, DaLian, China; |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1158/1538-7445.am2025-7459 |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Abstract 7459: The anticancer effects of brusatol are mediated by PPAR-γ/ME1-driven glycolysis in intrahepatic cholangiocarcinoma |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11072 |
| primary_topic.field.id | https://openalex.org/fields/13 |
| primary_topic.field.display_name | Biochemistry, Genetics and Molecular Biology |
| primary_topic.score | 0.9957000017166138 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1312 |
| primary_topic.subfield.display_name | Molecular Biology |
| primary_topic.display_name | Peroxisome Proliferator-Activated Receptors |
| related_works | https://openalex.org/W2899084033, https://openalex.org/W2327905510, https://openalex.org/W2082395821, https://openalex.org/W4313567692, https://openalex.org/W4405539940, https://openalex.org/W2347479114, https://openalex.org/W4386800154, https://openalex.org/W4399487644, https://openalex.org/W4404545952, https://openalex.org/W2363964973 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1158/1538-7445.am2025-7459 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S168522863 |
| best_oa_location.source.issn | 0008-5472, 1538-7445 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0008-5472 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Cancer Research |
| best_oa_location.source.host_organization | https://openalex.org/P4310320273 |
| best_oa_location.source.host_organization_name | American Association for Cancer Research |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320273 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Cancer Research |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1538-7445.am2025-7459 |
| primary_location.id | doi:10.1158/1538-7445.am2025-7459 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S168522863 |
| primary_location.source.issn | 0008-5472, 1538-7445 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0008-5472 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Cancer Research |
| primary_location.source.host_organization | https://openalex.org/P4310320273 |
| primary_location.source.host_organization_name | American Association for Cancer Research |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320273 |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Cancer Research |
| primary_location.landing_page_url | https://doi.org/10.1158/1538-7445.am2025-7459 |
| publication_date | 2025-04-21 |
| publication_year | 2025 |
| referenced_works_count | 0 |
| abstract_inverted_index.1 | 382 |
| abstract_inverted_index.a | 6, 37, 82, 135, 153, 169, 250, 282, 318 |
| abstract_inverted_index.(p | 156, 215, 256 |
| abstract_inverted_index.We | 80 |
| abstract_inverted_index.as | 166, 281, 317 |
| abstract_inverted_index.by | 10, 164, 168, 292, 362 |
| abstract_inverted_index.in | 63, 76, 85, 125, 152, 171, 179, 222, 249, 253, 269, 290, 365 |
| abstract_inverted_index.is | 5, 16, 34 |
| abstract_inverted_index.nr | 396 |
| abstract_inverted_index.of | 32, 61, 84, 100, 137, 149, 192, 264, 272, 279, 312, 334, 358, 371 |
| abstract_inverted_index.on | 88, 102 |
| abstract_inverted_index.or | 241 |
| abstract_inverted_index.to | 28, 71, 96, 116 |
| abstract_inverted_index.ATP | 174 |
| abstract_inverted_index.Apr | 386 |
| abstract_inverted_index.ICC | 33, 64, 77, 90, 126, 150, 180, 223, 291 |
| abstract_inverted_index.IL. | 389 |
| abstract_inverted_index.In: | 369 |
| abstract_inverted_index.Kai | 347 |
| abstract_inverted_index.Our | 298 |
| abstract_inverted_index.RNA | 201 |
| abstract_inverted_index.Res | 394 |
| abstract_inverted_index.The | 355 |
| abstract_inverted_index.Xu, | 346 |
| abstract_inverted_index.and | 21, 50, 94, 105, 110, 147, 176, 199, 203, 227, 320, 336 |
| abstract_inverted_index.are | 360 |
| abstract_inverted_index.for | 325, 331, 339, 375 |
| abstract_inverted_index.its | 11, 73, 315 |
| abstract_inverted_index.new | 335 |
| abstract_inverted_index.the | 30, 54, 58, 67, 98, 129, 144, 190, 211, 232, 243, 261, 265, 270, 277, 294, 304, 309, 332, 372 |
| abstract_inverted_index.via | 239 |
| abstract_inverted_index.was | 114, 131, 161 |
| abstract_inverted_index.2025 | 385 |
| abstract_inverted_index.Goel | 351 |
| abstract_inverted_index.HK2, | 197 |
| abstract_inverted_index.ICC. | 326, 340 |
| abstract_inverted_index.Luo, | 348 |
| abstract_inverted_index.Part | 381 |
| abstract_inverted_index.This | 327 |
| abstract_inverted_index.aims | 70 |
| abstract_inverted_index.axis | 268 |
| abstract_inverted_index.cell | 91, 103 |
| abstract_inverted_index.from | 41 |
| abstract_inverted_index.hope | 330 |
| abstract_inverted_index.poor | 22 |
| abstract_inverted_index.role | 263 |
| abstract_inverted_index.safe | 319 |
| abstract_inverted_index.that | 208, 285, 303 |
| abstract_inverted_index.with | 18, 122, 236, 246 |
| abstract_inverted_index.(ICC) | 4 |
| abstract_inverted_index.(PA): | 391 |
| abstract_inverted_index.2025; | 380 |
| abstract_inverted_index.7459. | 397 |
| abstract_inverted_index.AACR; | 392 |
| abstract_inverted_index.Ajay, | 352 |
| abstract_inverted_index.Fang, | 350 |
| abstract_inverted_index.LDHA. | 200 |
| abstract_inverted_index.PFK1, | 198 |
| abstract_inverted_index.These | 274 |
| abstract_inverted_index.Wang, | 344 |
| abstract_inverted_index.Yuhan | 349 |
| abstract_inverted_index.agent | 284 |
| abstract_inverted_index.assay | 188 |
| abstract_inverted_index.cells | 151 |
| abstract_inverted_index.chain | 185 |
| abstract_inverted_index.dense | 12 |
| abstract_inverted_index.human | 89 |
| abstract_inverted_index.lines | 92 |
| abstract_inverted_index.novel | 26 |
| abstract_inverted_index.siRNA | 240 |
| abstract_inverted_index.study | 69 |
| abstract_inverted_index.tumor | 8 |
| abstract_inverted_index.vitro | 86 |
| abstract_inverted_index.which | 15, 218 |
| abstract_inverted_index.0.01), | 258 |
| abstract_inverted_index.0.05), | 217 |
| abstract_inverted_index.0.05). | 158 |
| abstract_inverted_index.25-30; | 387 |
| abstract_inverted_index.Annual | 378 |
| abstract_inverted_index.Brucea | 42 |
| abstract_inverted_index.Cancer | 376, 393 |
| abstract_inverted_index.GLUT1, | 196 |
| abstract_inverted_index.Guixin | 353 |
| abstract_inverted_index.Hence, | 24 |
| abstract_inverted_index.Zhang. | 354 |
| abstract_inverted_index.assess | 97 |
| abstract_inverted_index.cells. | 78, 127, 181, 224 |
| abstract_inverted_index.genes, | 194 |
| abstract_inverted_index.impact | 99 |
| abstract_inverted_index.likely | 219 |
| abstract_inverted_index.manner | 155 |
| abstract_inverted_index.marked | 251 |
| abstract_inverted_index.offers | 329 |
| abstract_inverted_index.remain | 65 |
| abstract_inverted_index.series | 83, 136 |
| abstract_inverted_index.Caiming | 345 |
| abstract_inverted_index.Format: | 342 |
| abstract_inverted_index.HuCCT1) | 95 |
| abstract_inverted_index.Meeting | 379 |
| abstract_inverted_index.PPAR-γ | 237, 244 |
| abstract_inverted_index.RNA-seq | 233 |
| abstract_inverted_index.RT-qPCR | 226 |
| abstract_inverted_index.Reverse | 182 |
| abstract_inverted_index.effects | 60, 311, 357 |
| abstract_inverted_index.further | 132, 259 |
| abstract_inverted_index.glucose | 172 |
| abstract_inverted_index.improve | 29 |
| abstract_inverted_index.lactate | 177 |
| abstract_inverted_index.outcome | 31 |
| abstract_inverted_index.pathway | 111, 130, 204, 214, 245, 307 |
| abstract_inverted_index.present | 68 |
| abstract_inverted_index.provide | 300 |
| abstract_inverted_index.results | 230 |
| abstract_inverted_index.through | 134 |
| abstract_inverted_index.various | 45 |
| abstract_inverted_index.western | 228 |
| abstract_inverted_index.&lt; | 157, 216, 257 |
| abstract_inverted_index.(Regular | 383 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Although | 53 |
| abstract_inverted_index.American | 373 |
| abstract_inverted_index.Brusatol | 141 |
| abstract_inverted_index.Chicago, | 388 |
| abstract_inverted_index.Citation | 341 |
| abstract_inverted_index.Methods: | 79 |
| abstract_inverted_index.Research | 377 |
| abstract_inverted_index.Results: | 140 |
| abstract_inverted_index.Xiaoqing | 343 |
| abstract_inverted_index.activity | 160, 255 |
| abstract_inverted_index.analysis | 113, 206 |
| abstract_inverted_index.approach | 324 |
| abstract_inverted_index.blotting | 229 |
| abstract_inverted_index.brusatol | 62, 101, 123, 209, 280, 359 |
| abstract_inverted_index.critical | 262 |
| abstract_inverted_index.disrupts | 287 |
| abstract_inverted_index.effects. | 52 |
| abstract_inverted_index.evidence | 302 |
| abstract_inverted_index.exhibits | 44 |
| abstract_inverted_index.fibrotic | 13 |
| abstract_inverted_index.findings | 275, 299 |
| abstract_inverted_index.identify | 117 |
| abstract_inverted_index.improved | 337 |
| abstract_inverted_index.inhibits | 210 |
| abstract_inverted_index.invasion | 148 |
| abstract_inverted_index.isolated | 40 |
| abstract_inverted_index.markedly | 162 |
| abstract_inverted_index.mediated | 361 |
| abstract_inverted_index.mediates | 308 |
| abstract_inverted_index.molecule | 39 |
| abstract_inverted_index.outcome. | 23 |
| abstract_inverted_index.pathway. | 296 |
| abstract_inverted_index.pathways | 120 |
| abstract_inverted_index.reaction | 186 |
| abstract_inverted_index.resulted | 248 |
| abstract_inverted_index.specific | 118 |
| abstract_inverted_index.studies. | 139 |
| abstract_inverted_index.unclear, | 66 |
| abstract_inverted_index.(RT-qPCR) | 187 |
| abstract_inverted_index.Brusatol, | 36 |
| abstract_inverted_index.brusatol, | 165, 313 |
| abstract_inverted_index.conducted | 81 |
| abstract_inverted_index.confirmed | 189 |
| abstract_inverted_index.effective | 321 |
| abstract_inverted_index.evidenced | 167 |
| abstract_inverted_index.findings. | 234 |
| abstract_inverted_index.including | 48, 195 |
| abstract_inverted_index.inhibited | 143 |
| abstract_inverted_index.javanica, | 43 |
| abstract_inverted_index.malignant | 7 |
| abstract_inverted_index.molecular | 55 |
| abstract_inverted_index.performed | 115 |
| abstract_inverted_index.potential | 75, 278, 316, 328 |
| abstract_inverted_index.reduction | 170, 252 |
| abstract_inverted_index.regulates | 220 |
| abstract_inverted_index.secretion | 178 |
| abstract_inverted_index.signaling | 119, 213, 267, 306 |
| abstract_inverted_index.steroidal | 38 |
| abstract_inverted_index.suggested | 207 |
| abstract_inverted_index.targeting | 293 |
| abstract_inverted_index.treatment | 124, 323 |
| abstract_inverted_index.validated | 133 |
| abstract_inverted_index.(HCCC-9810 | 93 |
| abstract_inverted_index.Glycolytic | 159 |
| abstract_inverted_index.anticancer | 51, 356 |
| abstract_inverted_index.associated | 17, 121 |
| abstract_inverted_index.biological | 46 |
| abstract_inverted_index.compelling | 301 |
| abstract_inverted_index.developing | 25 |
| abstract_inverted_index.enrichment | 112, 205 |
| abstract_inverted_index.essential. | 35 |
| abstract_inverted_index.expression | 238 |
| abstract_inverted_index.glycolysis | 106, 221, 364 |
| abstract_inverted_index.glycolytic | 254, 288 |
| abstract_inverted_index.inhibiting | 242 |
| abstract_inverted_index.mechanisms | 56 |
| abstract_inverted_index.metabolism | 289 |
| abstract_inverted_index.migration, | 146 |
| abstract_inverted_index.polymerase | 184 |
| abstract_inverted_index.regulation | 271 |
| abstract_inverted_index.resistance | 20 |
| abstract_inverted_index.sequencing | 109, 202 |
| abstract_inverted_index.strategies | 27 |
| abstract_inverted_index.supporting | 314 |
| abstract_inverted_index.suppressed | 163 |
| abstract_inverted_index.treatments | 338 |
| abstract_inverted_index.underlying | 57 |
| abstract_inverted_index.underscore | 276 |
| abstract_inverted_index.Abstracts); | 384 |
| abstract_inverted_index.Association | 374 |
| abstract_inverted_index.Background: | 1 |
| abstract_inverted_index.Conclusion: | 297 |
| abstract_inverted_index.Interfering | 235 |
| abstract_inverted_index.PPAR-γ/ME1 | 212, 266, 295, 305 |
| abstract_inverted_index.Proceedings | 370 |
| abstract_inverted_index.[abstract]. | 368 |
| abstract_inverted_index.activities, | 47 |
| abstract_inverted_index.anti-cancer | 59, 310 |
| abstract_inverted_index.development | 333 |
| abstract_inverted_index.effectively | 286 |
| abstract_inverted_index.experiments | 87 |
| abstract_inverted_index.glycolysis. | 273 |
| abstract_inverted_index.integrative | 322 |
| abstract_inverted_index.investigate | 72 |
| abstract_inverted_index.mechanistic | 138 |
| abstract_inverted_index.production, | 175 |
| abstract_inverted_index.regulation. | 107 |
| abstract_inverted_index.reinforcing | 260 |
| abstract_inverted_index.therapeutic | 74, 283 |
| abstract_inverted_index.Furthermore, | 128 |
| abstract_inverted_index.Intrahepatic | 2 |
| abstract_inverted_index.Philadelphia | 390 |
| abstract_inverted_index.chemotherapy | 19 |
| abstract_inverted_index.consumption, | 173 |
| abstract_inverted_index.corroborated | 231 |
| abstract_inverted_index.intrahepatic | 366 |
| abstract_inverted_index.Rosiglitazone | 247 |
| abstract_inverted_index.Subsequently, | 225 |
| abstract_inverted_index.characterized | 9 |
| abstract_inverted_index.proliferation | 104 |
| abstract_inverted_index.significantly | 142 |
| abstract_inverted_index.Transcriptomic | 108 |
| abstract_inverted_index.downregulation | 191 |
| abstract_inverted_index.proliferation, | 145 |
| abstract_inverted_index.anti-inflammatory | 49 |
| abstract_inverted_index.microenvironment, | 14 |
| abstract_inverted_index.PPAR-γ/ME1-driven | 363 |
| abstract_inverted_index.cholangiocarcinoma | 3, 367 |
| abstract_inverted_index.glycolysis-related | 193 |
| abstract_inverted_index.concentration-dependent | 154 |
| abstract_inverted_index.transcription-quantitative | 183 |
| abstract_inverted_index.2025;85(8_Suppl_1):Abstract | 395 |
| cited_by_percentile_year | |
| countries_distinct_count | 2 |
| institutions_distinct_count | 6 |
| citation_normalized_percentile.value | 0.13055651 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |